Pulmonary Function and Persistent Clinical Symptoms in Children and Their Parents 12 Months After Mild SARS-CoV-2 Infection.
COVID-19
SARS-CoV-2
adolescents
children
convalescence
spirometry
Journal
Frontiers in pediatrics
ISSN: 2296-2360
Titre abrégé: Front Pediatr
Pays: Switzerland
ID NLM: 101615492
Informations de publication
Date de publication:
2022
2022
Historique:
received:
11
03
2022
accepted:
09
05
2022
entrez:
18
7
2022
pubmed:
19
7
2022
medline:
19
7
2022
Statut:
epublish
Résumé
Pulmonary involvement is the leading cause of morbidity and mortality after severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. Long-term impairment has been reported in adults with severe infection. However, most infections cause only mild symptoms or are even asymptomatic, especially in children. There is insufficient evidence regarding pulmonary outcome measures in mild SARS-CoV-2. The objectives of this study were to determine spirometry parameters after SARS-CoV-2 infection and correlate those with reported persisting symptoms in children, adolescents, and adults. Data on clinical symptoms during acute infection as well as SARS-CoV-2 serology results were recorded. Twelve months after infection, spirometry was performed and information on persisting symptoms was collected using a structured questionnaire. 182 participants (108 SARS-CoV-2 positive) from 48 families were included; 53 children (< 14 years), 34 adolescents and young adults (14-25 years), and 95 adults. Spirometry values did not significantly differ between the particular subgroups of the cohort (adults, adolescents, children; infected and non-infected individuals). Adults reported more symptoms during acute infection as well more persisting fatigue (29.7% of participants), reduced physical resilience (34.4%), and dyspnea (25.0%) 12 months after infection than adolescents (fatigue 26.7%, reduced physical resilience 20%, and 0% dyspnea) and children (4%, 0%, 0%, respectively). There was no correlation between persistent subjective symptoms and spirometry results. Children and adolescents are less affected than adults by acute SARS-CoV-2 as well as by post-infection persistent symptoms. Spirometry was not able to demonstrate any differences between healthy individuals and participants who had suffered from mild SARS-CoV-2 12 months after the infection.
Sections du résumé
Background
UNASSIGNED
Pulmonary involvement is the leading cause of morbidity and mortality after severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. Long-term impairment has been reported in adults with severe infection. However, most infections cause only mild symptoms or are even asymptomatic, especially in children. There is insufficient evidence regarding pulmonary outcome measures in mild SARS-CoV-2. The objectives of this study were to determine spirometry parameters after SARS-CoV-2 infection and correlate those with reported persisting symptoms in children, adolescents, and adults.
Methods
UNASSIGNED
Data on clinical symptoms during acute infection as well as SARS-CoV-2 serology results were recorded. Twelve months after infection, spirometry was performed and information on persisting symptoms was collected using a structured questionnaire. 182 participants (108 SARS-CoV-2 positive) from 48 families were included; 53 children (< 14 years), 34 adolescents and young adults (14-25 years), and 95 adults.
Results
UNASSIGNED
Spirometry values did not significantly differ between the particular subgroups of the cohort (adults, adolescents, children; infected and non-infected individuals). Adults reported more symptoms during acute infection as well more persisting fatigue (29.7% of participants), reduced physical resilience (34.4%), and dyspnea (25.0%) 12 months after infection than adolescents (fatigue 26.7%, reduced physical resilience 20%, and 0% dyspnea) and children (4%, 0%, 0%, respectively). There was no correlation between persistent subjective symptoms and spirometry results.
Discussion
UNASSIGNED
Children and adolescents are less affected than adults by acute SARS-CoV-2 as well as by post-infection persistent symptoms. Spirometry was not able to demonstrate any differences between healthy individuals and participants who had suffered from mild SARS-CoV-2 12 months after the infection.
Identifiants
pubmed: 35844730
doi: 10.3389/fped.2022.894331
pmc: PMC9279894
doi:
Types de publication
Journal Article
Langues
eng
Pagination
894331Informations de copyright
Copyright © 2022 Bode, Haendly, Fabricius, Mayer, Zernickel, Haddad, Frieh, Elling, Renk, Stich, Jacobsen, Debatin and Janda.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Am Coll Radiol. 2020 Jun;17(6):701-709
pubmed: 32283052
MMWR Morb Mortal Wkly Rep. 2020 Apr 10;69(14):422-426
pubmed: 32271728
Histopathology. 2020 Aug;77(2):198-209
pubmed: 32364264
Nat Commun. 2022 Jan 10;13(1):128
pubmed: 35013206
Eur Respir J. 2021 Apr 29;57(4):
pubmed: 33303540
Intensive Care Med. 2020 Oct;46(10):1863-1872
pubmed: 32816098
Lancet Infect Dis. 2020 May;20(5):533-534
pubmed: 32087114
JAMA Pediatr. 2021 Jun 1;175(6):586-593
pubmed: 33480966
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Eur Respir J. 2021 Feb 25;57(2):
pubmed: 33479105
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Lancet Respir Med. 2020 Apr;8(4):420-422
pubmed: 32085846
J Med Virol. 2021 Feb;93(2):1013-1022
pubmed: 32729939
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
Eur Respir J. 2021 Jan 28;57(1):
pubmed: 33361097
Pneumologie. 2020 Aug;74(8):496-504
pubmed: 32583378
Front Pediatr. 2021 May 13;9:621019
pubmed: 34084763
Front Pediatr. 2022 Apr 25;10:851008
pubmed: 35547532
J Infect. 2021 Mar;82(3):378-383
pubmed: 33450302
N Engl J Med. 2020 Jul 9;383(2):120-128
pubmed: 32437596
Emerg Infect Dis. 2021 Dec;27(12):3009-3019
pubmed: 34695369
Ann Intern Med. 2020 Aug 18;173(4):268-277
pubmed: 32374815
Infection. 2021 Feb;49(1):153-157
pubmed: 32725597
JAMA Netw Open. 2021 Jan 4;4(1):e2036142
pubmed: 33502487
JAMA. 2021 May 18;325(19):2015-2016
pubmed: 33825846
Respir Med. 2021 Jun;182:106421
pubmed: 33901788
Respir Care. 2021 Nov;66(11):1691-1698
pubmed: 34493607
Clin Microbiol Infect. 2021 Jan;27(1):89-95
pubmed: 32979574
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Ann Intern Med. 2021 Sep;174(9):1252-1260
pubmed: 34224254
Eur Respir J. 2021 Apr 29;57(4):
pubmed: 33419891
Lancet Child Adolesc Health. 2021 Oct;5(10):708-718
pubmed: 34358472
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
Lancet Respir Med. 2021 Jul;9(7):747-754
pubmed: 33964245
Pneumologie. 2015 Mar;69(3):147-64
pubmed: 25750095
Lancet. 2021 Aug 28;398(10302):747-758
pubmed: 34454673
Eur J Clin Invest. 2021 Aug;51(8):e13603
pubmed: 33998683
Lancet Child Adolesc Health. 2020 Sep;4(9):653-661
pubmed: 32593339
EClinicalMedicine. 2021 Nov;41:101159
pubmed: 34693230
Pulmonology. 2021 Jul-Aug;27(4):328-337
pubmed: 33262076
Am J Respir Crit Care Med. 2019 Oct 15;200(8):e70-e88
pubmed: 31613151
JCI Insight. 2021 Jul 22;6(14):
pubmed: 34111030
Lancet Child Adolesc Health. 2022 Apr;6(4):230-239
pubmed: 35143770
BMJ. 2020 May 29;369:m1996
pubmed: 32471884
Pneumologie. 2021 Nov;75(11):869-900
pubmed: 34474488
Ann Intern Med. 2021 May;174(5):655-662
pubmed: 33481642
JAMA. 2021 Jul 15;:
pubmed: 34264266
Respir Res. 2021 Jan 21;22(1):29
pubmed: 33478527
MMWR Morb Mortal Wkly Rep. 2020 Jul 31;69(30):993-998
pubmed: 32730238
Eur Respir J. 2021 Apr 29;57(4):
pubmed: 33303539